Amar Jyoti Kalita

Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors

Karen A. Gelmon, A. Tolcher, Michael A. Carducci et al. · Journal of Clinical Oncology · 2005 · 18 citations

Medicine, Oncology, Pharmacology +17

A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS)

Jeffrey E. Lancet, Gwen Nichols, Sarit Assouline et al. · Journal of Clinical Oncology · 2007 · 13 citations

Medicine, Oncology, Pharmacology +15

Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors

Michael A. Carducci, Lillian L. Siu, Rana Sullivan et al. · Journal of Clinical Oncology · 2006 · 11 citations

Medicine, Oncology, Pharmacology +13